• 동력기계공학회지
• /
• 제15권5호
• /
• pp.72-76
• /
• 2011

In this work, the parameter optimization for thermal-sprayed Al/SiC composites have been designed by $L_9(3^4)$ orthogonal array and analysis of variance(ANOVA). Al/SiC composites were fabricated by flame spray process on steel substrate. The hardness of composites were measured using micro-vickers hardness tester, and these results were analyzed by ANOVA. The ANOVA results showed that the oxygen gas flow, powder feed rate and spray distance affect on the hardness of the Al/SiC composites. From the ANOVA results, the optimal combination of the flame spray parameters could be extracted. It was considered that experimental design using orthogonal array and ANOVA was efficient to determine optimal parameter of thermal-sprayed Al/SiC composites.

• 응용통계연구
• /
• 제15권2호
• /
• pp.337-354
• /
• 2002

본 논문에서는 오차성분이 계열상관을 갖는 불균형 랜덤모형에서 분산성분의 추정방법에 대하여 연구하였다. 분산성분에 대한 추정량으로 조건부 ANOVA(cANOVA), ML및 REML추정량등을 유도하였으며, 계열상관값과 불균형의 정도에 따른 추정량의 변동성을 추정량의 분위수를 이용하는 EQDGs플롯을 이용하여 비교하였다. 모의실험결과 cANOVA추정방법은 불균형의 정도에는 추정량값이 크게 영향을 받지 않는 것으로 나타났으나 계열상관값의 증가에 따라서는 변동성을 보이고 있다. 불균형의 정도와 계열상관값을 동시에 고려하는 경우에는 ML추정방법이 cANOVA, REML추정방법보다 변동성이 안정적으로 나타났다.

• 한국생물정보학회:학술대회논문집
• /
• 한국생물정보시스템생물학회 2001년도 제2회 생물정보 워크샵 (DNA Chip Bioinformatics)
• /
• pp.97-115
• /
• 2001

cDNA microarray technology allows the monitoring of expression levels for thousands of genes simultaneously. Many statistical analysis tools become widely applicable to the analysis of cDNA microarray data. In this talk, we consider a two-way ANOVA model to differentiate genes that have high variability and ones that do not. Using this model, we detect genes that have different gene expression profiles among experimental groups. The two-way ANOVA model is illustrated using cDNA microarrays of 3,800 genes obtained in an experiment to search for changes in gene expression profiles during neuronal differentiation of cortical stem cells.

• Advances in concrete construction
• /
• 제11권4호
• /
• pp.285-298
• /
• 2021

This study focused on experimental evaluation of mechanical properties of pervious concrete mixtures with the aim of achieving higher values of strength while considering the associated costs. The effectiveness of key parameters, including cement content, water to cement ratio (W/C), aggregate to cement ratio (A/C), and sand replacement was statistically analyzed using paired-samples t-test, Taguchi method and one-way ANOVA. Taguchi analysis determined that in general, the role of W/C was more significant in increasing strength, both compressive and flexural, than cement content and A/C. It was found that increase in replacing percent of coarse aggregate with sand could undermine specimens to percolate water, though one-way ANOVA analysis determined statistically significant increases in values of strength of mixtures. Cost analysis revealed that higher strengths did not necessarily correspond to higher costs; in addition, increasing the cement content was not an appropriate scenario to optimize both strength and cost. In order to obtain the optimal values, response surface method (RSM) was carried out. RSM optimization helped to find out that W/C of 0.40, A/C of 4.0, cement content of about 330 kg/m3 and replacing about 12% of coarse aggregate with sand could result in the best values for strength and cost while maintaining adequate permeability.

• Advances in concrete construction
• /
• 제6권6호
• /
• pp.611-629
• /
• 2018

The objective of present study is to investigate the effect of granulated blast furnace slag (GBS) as partial substitution of natural sand on behaviour of cement mortar. For this, the methods of factorial design with water cement (w/c) ratio and incorporation percentages of GBS as replacement of natural fine aggregate i.e., GBS(%) as factors are followed. The levels of factor w/c ratio are fixed at 0.4, 0.45, and 0.5 and the levels of factor GBS(%) are kept fixed as 0%, 20%, 40%, 60%, 80% and 100%. The compressive strength (CS) of mortar after 3, 7, 14, 28, 56 and 90 days, and water absorption (WA) are chosen as responses of the study. Analysis of variance (ANOVA) of experimental results has been carried out and those are illustrated by ANOVA tables, main effect and interaction plots. The results of study depict that the selected factors have substantial influence on the strength and WA of mortar. However, the interaction of factors has no substantial impact on CS and WA of mixes.

• Journal of Pharmaceutical Investigation
• /
• 제24권2호
• /
• pp.49-55
• /
• 1994

Bioequivalence test of commercially available rifampicin capsules was performed. Sixteen volunteers were divided into 2 groups and the reference and test drug were given orally (450 mg) by cross-over design. Statistical evaluation of AUC, $C_{max}\;and\;T_{max}$ involved an analysis of variance (ANOVA). The differences of mean value in AUC, $C_{max}\;and\;T_{max}$ between the reference and test drug were within 20% with reference drug. ANOVA showed no significant differences for ‘between group’, ‘drug’ and ‘period’, but not for ‘between subjects’. The power of test $(1-{\beta})\;of\;AUC\;and\;$C_{max}$ was larger than 0.8 and the confidence of bioavailability was $within\;{\pm}20%$. From these results, it was concluded that the two preparations were bioequivalent for AUC and $C_{max}$, but was not for $T_{max}$.

• Journal of Pharmaceutical Investigation
• /
• 제24권2호
• /
• pp.67-72
• /
• 1994

Bioequivalence (BE) test of biphenyl dimethyl dicarboxylate (DDB) tablets was performed. Normal healthy male volunteers (n = 20) were randomly divided into 2 groups, and reference $(Nissel{\circledR})$ and test $(Livital{\circledR})$ tablets of DDB $(25mg{\times}8\;Tab.\;= \;200\;mg)$ were given orally by balanced two-period cross-over design. The serum concentration was determined by high performance liquid chromatography. The pharmacokinetic parameters, AUC, $C_{max}$, and $T_{max}$ obtained after drug administration were statistically analyzed. Statistical evaluation of the data involved an analysis of variance (ANOVA) for cross-over design. The results were within 20% differences of mean value in AUC, $C_{max}$, and $T_{max}$ between reference and test tablets. The results of ANOVA showed no significant differences for "between group or subject" and "period". The test tablet was bioequivalent with the reference tablet in the AUC, $C_{max}$, and $T_{max}$.

• 응용통계연구
• /
• 제17권3호
• /
• pp.419-430
• /
• 2004

마이크로어레이 기술은 한번에 수만 개의 유전자를 동시에 분석할 수 있는 고효율, 고가의 새로운 연구 도구로 자리잡았으며 마이크로어레이 실험 자료의 올바른 분석을 위해서는 실험 목적에 맞는 실험계획법의 확립과 통계분석법의 적용이 중요하다 본 논문에서는 마이크로어레이 자료에서 여러 군 사이에서 발현의 차이를 보이는 유전자를 찾을 수 있는 되돌림 설계를 소개하고 ANOVA 모형을 이용하여 분석하는 방법을 제시한다. 연세대학교 암전이 연구센터의 되돌림 설계를 이용한 백혈병 자료를 MA-ANOVA(Wu et. al.(2003))를 이용하여 분석하였다

• Archives of Pharmacal Research
• /
• 제18권4호
• /
• pp.237-242
• /
• 1995

For the vioequivalence study of two ceftriaxone injection formulations ($Rocephin{\circledR}$ ; Roche, and Triaxone ; Hanmi0, the HPLC analytical method for the analysis of ceftriaxone in plasma was used. Fourteen healthy volunteers completed the study and each subject were IM in jected signle doses (1 g) of the test and the reference formulations in a two-way crossover design with an one week drug free interval between doses. Following each administration, plasma concentrations of ceftrixone were monitored over a period of 24 h. Bioequivalence parameters $AUC_{24th}, {\;}T_{max}, {\;}C_{max}$ and MRT determined from the data obtained for the two formulations were examined by analyses of variance (ANOVA) and other criteria and tests for bioequivalence. Results of ANOVA and confidence limits of test/reference ratios of $AUC_{24th}, {\;}T_{max}, {\;}C_{max}$ and MRT, and statistical tests indicated the bioequivalence of the two formulations (i.e., test/reference ratio was within $100{\pm}20%$) except for $T_{max}$ The mean of $T_{max}$ showed only 6. 9% difference from the reference but the detection limit was 22.5% which is slightly over the 20% criteria. No pharmacokinetic parameters including Ka, Kel, Vd and Cl indicated significant difference in between the two fomulations. It was concluded that the data yielded fro the two cefriaxone formulations demonstrated that they were bioequivalent.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.65-71
• /
• 2003

Terbinafine is a synthetic allylamine that is available in an oral formulation and is used at a dosage of 250mg/day. It is used as an active antifungal agent and inhibits the fungal enzyme squalene epoxidase, which leads to the accumulation of the sterol squalene, which is toxic to the organism. The purpose of the present study was to evaluate the bioequivalence of two terbinafine tablets, Lamisil (Novartis Korea Ltd.) and Terbinex (C-TRI Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 26.00$\pm$2.57 year in age and 70.51$\pm$9.36 kg in body weight, were divided into two groups and a randomized 2${\times}$2 cross-over study was employed. After one tablet containing 125 mg of terbinafine was orally administered, blood was taken at predetermined time intervals and the concentrations of terbinafine in plasma were determined using HPLC with UV detector. Pharmacokinetic parameters such as AUC, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC, $C_{max}$ and $T_{max}$ between two tablets were －4.191％, 5.223％ and －25.720％, respectively when calculated against the Lamisil, tablet. The powers (1-$\beta$) for AUC, $C_{max}$ and $T_{max}$ were 81％, 87％ and below 60％, respectively. Minimum detectable differences(.il) at alpha=O.1 and 1-/3=0.8 were less than 20％ (e.g., 19.72％ and 17.77％ for AUC and $C_{max}$, respectively). But minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 for $T_{max}$ were more than 20％ (e.g., 26.25％). The 90％ confidence intervals were within $\pm$20％ (e.g., －17.440∼9.06 and －6.713∼17.160 for AUC and $C_{max}$ respectively). But 90％ confidence intervals for $T_{max}$ were not within $\pm$20％ (e.g., －43.346∼8.083). Another ANOVA test was conducted for logarithmically transformed AUC and $C_{max}$. These results showed that there are no significant differences in AUC and $C_{max}$ between the two formulations: The differences between the formulations in these log transformed parameters were all for less than 20％ (e.g., －4.19％ and 5.22％ for AUC and $C_{max}$, respectively). The 90％ confidence intervals for the log transformed data were not the acceptance range of log 0.8 to log 1.25 in AUC but the acceptance range of log 0.8 to log 1.25 in $C_{max}$ (e.g., log 1.13∼log 1.50 and log 0.94-log 1.22 for AUC and $C_{max}$ respectively). The major parameters, AUC and $C_{max}$ met the criteria of KFDA for bioequivalence although $T_{max}$ did not meet the criteria of KFDA (1998 year) for bioequivalence, indicating that Onfran tablet is bioequivalent to Zofran tablet. But in another ANOVA test AUC did not meet the criteria of KFDA (2002) for bioequivalence but $C_{max}$ met the criteria of KFDA (2002 year) for bioequivalence.or bioequivalence.equivalence.equivalence.equivalence.